ClinicalTrials.gg
RecruitingNCT06271057Updated Jun 4, 2026

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

A Phase 2 interventional study of golcadomide in Diffuse Large B-cell Lymphoma Refractory, Refractory Primary Mediastinal Large B-Cell Lymphoma and Refractory Transformed B-cell Non-Hodgkin Lymphoma, sponsored by The Lymphoma Academic Research Organisation. Recruiting at 13 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Primary conditionLymphoma, Large B-Cell, DiffuseRegistry: Lymphoma, B-CellReclassifiedWhy we changed it
Registry
Lymphoma, B-Cell — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Large B-Cell, Diffuse
Why
  1. The study's listed conditions name Lymphoma, Large B-Cell, Diffuse, a narrower term within Lymphoma, B-Cell.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by The Lymphoma Academic Research Organisation · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Lymphoma, Large B-Cell, Diffuse by The Lymphoma Academic Research Organisation — 2 open to participants now, 2 under way, none of them phase 3. Lymphoma, Large B-Cell, Diffuse · The Lymphoma Academic Research Organisation.

Started
2024
the only one that year
Phase 2
6 of 10
2 open now
Registered
9th of 10
by date

Among the 10 studies in Lymphoma, Large B-Cell, Diffuse by The Lymphoma Academic Research Organisation, this one is the only one that started in 2024, is one of 6 in phase 2, and was the 9th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

2 of the 10 studies in Lymphoma, Large B-Cell, Diffuse by The Lymphoma Academic Research Organisation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Lymphoma, Large B-Cell, Diffuse by The Lymphoma Academic Research Organisation, or all of them as a file.
02

Study summary

This study is an open-label, multicenter, proof of concept, phase 2 trial. Patients will be recruited over 18 months. Safety analysis will be performed with a stop of the enrollment after 3 patients have either 1 complete treatment cycle or permanently discontinued treatment whichever occurs first.

Approximatively 65 patients with aggressive large B-cell lymphoma (LBCL) (including diffuse large B-cell lymphoma (DLBCL), Primary mediastinal B-cell lymphoma (PMBCL), any transformed follicular or marginal zone lymphoma, high-grade B-cell lymphoma (HGBL)) will be enrolled in the study.

The duration of treatment with golcadomide (CELMoD) is 24 weeks with 6 cycles of 28 days (4 weeks), starting at 5 days after CAR-T cells infusion.

The primary objective of the study is to estimate the efficacy of golcadomide administered post-anti-CD19 CAR T-cell infusion, Efficacy determination will be based upon the primary endpoint of complete metabolic response (CMR) rate at 3 months after infusion of anti-CD19 CAR T-cell assessed by study investigator.

03

Conditions studied

  • Diffuse Large B-cell Lymphoma Refractory
  • Refractory Primary Mediastinal Large B-Cell Lymphoma
  • Refractory Transformed B-cell Non-Hodgkin Lymphoma
  • Refractory High Grade B-Cell Lymphoma

Browse trials for

Keywords

  • eligible for CAR T-cells therapy
04

In context

Lymphoma, Large B-Cell, Diffuse Reclassified

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

This study's planned enrollment of 65 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Lead sponsor

The Lymphoma Academic Research Organisation is the lead sponsor of 60 studies on the registry; 12 are open to participants now.

Compared within Lymphoma, Large B-Cell, Diffuse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, B-Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient who understood and voluntarily signed and dated an prior to any study-specific assessments/procedures being conducted
  2. Adults patients (≥ 18-year-old at the time of signing the informed consent form; no upper age limit)
  3. Eligible for any commercialized market authorized anti-CD19 CAR T-cells
  4. Performance Status 0, 1, or 2
  5. With aggressive large B-cell lymphoma, including:

    • diffuse large B-cell lymphoma
    • Primary mediastinal B-cell lymphoma
    • Any transformed follicular or marginal zone lymphoma
    • high-grade B-cell lymphoma (HGBL) Note: patients with Central Nervous System (CNS) involvement could be included but not patients with primary CNS lymphoma
  6. Available for centralized review
  7. With a CAR T-cells indication as soon as treatment no later than in 4th line, previously validated by the multidisciplinary tumor board Note: Any treatment performed prior to leukapheresis is considered a line of treatment
  8. Total MetabolicTumor Volume (TMTV) > 80 ml, measured by centralized review, on standard18FDG-PET (positron emission tomography) done just before starting CAR T-cells procedure (i.e., D-13 +/- 4 days before lymphodepletion)
  9. (as estimated by Modification of Diet in Renal Disease () if > 60-year-old or Cockcroft-Gault if \<60yo) >45 mL/min,
  10. Adequate hepatic function:

    • /alanine aminotransferase (ALT/AST) ≤ 3.0 x . (Note: In the case of documented liver involvement by lymphoma, ALT/AST must be ≤ 5.0 x ULN)
    • Serum total ≤ 2.0 mg/dL (34 μmol/L) (Note: In the case of Gilbert's syndrome, or documented liver or pancreatic involvement by lymphoma, serum total bilirubin must be ≤ 3.0 mg/dL (51 μmol/L))
  11. Patient covered by any social security system (France)
  12. Patient who understands and speaks one of the country official languages, unless local regulation authorizes independent translators
  13. :

    • For women of : Agreement to remain abstinent (refrain from heterosexual intercourse) or use two adequate methods of contraception, including at least one highly effective method, as soon as consent is signed, during the treatment period (including periods of treatment interruption), and for at least 28 days after the last dose of golcadomide, Women must refrain from donating eggs during this same period.

Exclusion criteria

Exclusion Criteria:

  1. History of other than non-melanoma skin cancer or carcinoma in situ (eg, cervix, bladder, breast) unless disease free for at least 3 years
  2. Presence or suspicion of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management; simple urinary tract infection and uncomplicated bacterial pharyngitis are permitted if responding to active treatment and after consultation with the sponsor's medical monitor
  3. History of (HIV) infection or acute or chronic active or C infection; subjects with history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing per current Infectious Diseases Society of America guidelines or applicable country guidelines
  4. Significant pulmonary function impairment and oxygen saturation (SaO2) \< 92% on room air
  5. Significant cardiovascular disease such as Class III or IV or Objective Class C or D cardiac disease (see appendix 07)
  6. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other cardiac disease within 6 months of enrollment
  7. History of severe immediate reaction to any of the agents used in this study
  8. Current treatment with strong /5 modulators (see appendix 13)
  9. Pregnant, planning to become pregnant or lactating Women of Child Bearing Potential
  10. Any significant medical conditions, laboratory abnormality or psychiatric illness likely to interfere with participation in this clinical study (according to the investigator's decision)
  11. Person deprived of his/her liberty by a judicial or administrative decision
  12. Person hospitalized without consent
  13. Adult person under legal protection
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
65 participants (estimated)

Study arms

  • Experimental
    golcadomide post CAR T-cells

    0.3 mg - Per Os - every week - 6 months

    Drug: golcadomide

Interventions

  • golcadomide 0.3 mg weekly from D+5 post CAR T-cells administration until D+166

    Also known as: BMS-986369, CC-99282

07

What researchers measure

Primary outcomes

  1. Complete metabolic response rate (CMR rate)

    efficacy of golcadomide administered post-anti-CD19 CAR T-cell infusion

    Time frame: 3 months

Secondary outcomes

  1. Objective response rate (ORR)

    incidence of either a complete (CMR) or a partial (PMR) metabolic response per the Lugano Classification (Cheson 2014) as determined by study investigators

    Time frame: at 1 month, 3 months, 6 months, 1 year and 2 years, from CAR-T infusion

  2. Objective response rate (ORR)

    determined by imaging central review

    Time frame: at 1 month and 3 months

  3. Complete response rate (CRR)

    percentage of complete response determined by investigator assessment classification

    Time frame: at 1 Month, 6 Months, 1 year, and 2 years

  4. Duration of response (DR)

    time from attainment of PMR or CMR to the date of first documented disease progression/relapse (based on investigator disease assessment (INV)) or death from any cause

    Time frame: 2 years

  5. Event-free survival (EFS)

    the time between CAR T-cells injection and death, disease progression, or start of subsequent new anti-lymphoma therapy including Stem Cell Transplant (SCT)

    Time frame: 2 years

  6. Progression-free survival (PFS)

    time from CAR T-cells injection to the first observation of documented disease progression/relapse (based on investigator disease assessment (INV)) or death

    Time frame: 2 years

  7. Time To Next anti-Lymphoma Treatment (TTNLT)

    from the date of CAR T-cells injection to the date of first documented administration of any new anti-lymphoma treatment

    Time frame: 2 years

  8. Overall survival (OS)

    from date of CAR T-cells injection to the date of death

    Time frame: 2 years

  9. Incidence of Adverse Events and Serious Adverse events

    Time frame: 2 years

08

Study locations

13 of 13 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Mar 2027, 33 months after the start.

Of 211 non-industry phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's planned 33 months is below that.

Counting every sponsor, half of 264 studies reached it within 52 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2024
First posted
Feb 21, 2024
StartActual
Jun 14, 2024
Primary completionEst.
Mar 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06271057
Lead sponsor
The Lymphoma Academic Research Organisation
Collaborators
Lymphoma Study Association
Responsible party
Sponsor
First posted
Feb 21, 2024
Start date
Jun 14, 2024
Primary completion
Mar 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jun 4, 2026

Study contacts

Stéphanie DOYEN
Contact
stephanie.doyen@lysarc.org
+33 4 27 01 27 36
Catherine THIEBLEMONT, Prof. Dr.
principal investigator · Hôpital Saint-Louis
Gabriel BRISOU, Prof. Dr.
principal investigator · Institut Paoli-Calmettes
François-Xavier GROS, Prof. Dr.
principal investigator · University Hospital, Bordeaux

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Golcadomide

Start the discussion